DBV Technologies (NASDAQ:DBVT) Trading Up 8.1% – Time to Buy?

DBV Technologies S.A. (NASDAQ:DBVT)’s stock price rose 8.1% during mid-day trading on Tuesday . The company traded as high as $16.70 and last traded at $16.8730. 163,793 shares were traded during trading, a decline of 45% from the average daily volume of 296,862 shares. The stock had previously closed at $15.61.

Analysts Set New Price Targets

Several research firms have recently commented on DBVT. Citizens Jmp raised their price objective on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DBV Technologies in a research note on Monday, June 29th. Wall Street Zen cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $48.50.

DBV Technologies Trading Down 2.1%

The firm’s fifty day simple moving average is $17.77 and its 200 day simple moving average is $19.68. The company has a market cap of $970.63 million, a price-to-earnings ratio of -3.63 and a beta of -0.95.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). The firm had revenue of $0.90 million during the quarter, compared to analyst estimates of $1.11 million. DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. As a group, sell-side analysts expect that DBV Technologies S.A. will post -0.38 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC increased its holdings in shares of DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after acquiring an additional 744 shares during the last quarter. Truvestments Capital LLC boosted its holdings in DBV Technologies by 71.3% in the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after purchasing an additional 1,620 shares in the last quarter. Allworth Financial LP acquired a new position in DBV Technologies in the fourth quarter valued at approximately $32,000. Royal Bank of Canada purchased a new position in DBV Technologies in the fourth quarter valued at approximately $34,000. Finally, Persistent Asset Partners Ltd purchased a new position in DBV Technologies in the fourth quarter valued at approximately $115,000. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.